MedTrace Logo

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

NCT05946369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2023-07-18

No results posted yet for this study

Summary

There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder).

In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to intravesical BCG therapy post trans-urethral resection of urinary bladder tumors for the non-invasive urinary bladder tumors.

Conditions

  • Urinary Bladder Cancer
  • Urinary Bladder Neoplasm
  • BCG
  • Trans Urethral Resection of a Bladder Tumor
  • Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions

DIAGNOSTIC_TEST

Neutrophil to lymphocyte ratio

Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2023-01-01
Completion
2023-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05946369 on ClinicalTrials.gov